Baseline characteristics
| Characteristic . | n (%)* . |
|---|---|
| Total no. of patients | 76 |
| Age, y | |
| Median (range) | 59 (40-76) |
| ≥65 | 21 (27.6) |
| Sex | |
| Male | 45 (59.2) |
| Female | 31 (40.8) |
| ECOG performance status | |
| 0-1 | 65 (85.5) |
| Unknown | 11 (14.5) |
| ISS stage | |
| I | 31 (40.8) |
| II | 31 (40.8) |
| III | 10 (13.2) |
| Unknown | 4 (5.3) |
| Cytogenetic risk by FISH† | |
| High | 27 (35.5) |
| del(17p) | 11 (14.5) |
| Ultra-high risk‡ | 8 (10.5) |
| Standard | 49 (64.5) |
| Serum β2-microglobulin, mg/L | |
| <3.5 | 45 (59.2) |
| ≥3.5 | 24 (31.6 |
| Unknown | 7 (9.2) |
| Characteristic . | n (%)* . |
|---|---|
| Total no. of patients | 76 |
| Age, y | |
| Median (range) | 59 (40-76) |
| ≥65 | 21 (27.6) |
| Sex | |
| Male | 45 (59.2) |
| Female | 31 (40.8) |
| ECOG performance status | |
| 0-1 | 65 (85.5) |
| Unknown | 11 (14.5) |
| ISS stage | |
| I | 31 (40.8) |
| II | 31 (40.8) |
| III | 10 (13.2) |
| Unknown | 4 (5.3) |
| Cytogenetic risk by FISH† | |
| High | 27 (35.5) |
| del(17p) | 11 (14.5) |
| Ultra-high risk‡ | 8 (10.5) |
| Standard | 49 (64.5) |
| Serum β2-microglobulin, mg/L | |
| <3.5 | 45 (59.2) |
| ≥3.5 | 24 (31.6 |
| Unknown | 7 (9.2) |
ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; ISS, International Staging System.
All data in the table are n (%), unless otherwise designated.
Defined per International Myeloma Working Group (IMWG): t(4;14), del(17p), t(14;16), t(14;20), nonhyperdiploidy and gain(1q).
High, risk ≥3 cytogenetic abnormalities.27